Documents - Marketing authorisation medicines for human use

53 documents Marketing authorisation medicines for human use

Enter search criteria

Fill in keyword(s) to narrow your search.

Fill in a starting date and a closing date for the period your query is about: DD-MM-YYYY

You can select a specific type of a document or publication you are looking for, such as press releases or speeches.

Product types and fees

The list of product types indicates the various product types handled by the MEB. The choice of the product type determines the ...

Publication | 01-01-2019

MEB 14: Parallel importation: marketing authorisation and maintenance

Parallel import is the importation – and subsequent marketing in the Netherlands – of a medicinal product authorised elsewhere in ...

Policy document | 08-11-2018

Question and answer document concerning changes not covered by the Variation Regulation 1234/2008 (as amended by Regulation 712/2012)

Policy document | 05-10-2018

Letter to stakeholders regarding the implementation of safety features under the Falsified Medicines Directive 2011/62/EU

The delegated Regulation on the characteristics of the safety features and the new medicine verification system will apply as of ...

Publication | 01-10-2018

Declaration by the applicant pertaining to the application for a Duplex marketing authorisation (Model I)

Directive | 18-06-2018

Declaration by the applicant pertaining to the application for a Duplex marketing authorisation (Model I) - Duplex with supplementary conditions

Directive | 18-06-2018

MEB 16: Duplex marketing authorisation

A duplex marketing authorisation is a marketing authorisation for a product of which the dossier is identical to that of a ...

Policy document | 18-06-2018

MEB 45: National implementation of additional risk minimisation measures

An important element of a risk management plan (RMP) is a clear description of the necessary measures in order to minimise the ...

Policy document | 11-06-2018

MEB 44: Direct Healthcare Professional Communications (DHPCs)

This document is based on the Guideline on Good Pharmacovigilance Practices (GVP) Module XV – Safety communication, and is aimed ...

Policy document | 11-06-2018

GS-list 15

The list of active substances in products that may qualify for sale general sale (GS list) was updated by the MEB on 30 May 2018. ...

Policy document | 30-05-2018